BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25478964)

  • 1. Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer.
    Negi LM; Jaggi M; Joshi V; Ronodip K; Talegaonkar S
    Int J Biol Macromol; 2015 Feb; 73():222-35. PubMed ID: 25478964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an
    Negi LM; Talegaonkar S; Jaggi M; Verma AK
    J Drug Target; 2019 Feb; 27(2):183-192. PubMed ID: 29972336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
    Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
    Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
    Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
    Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
    Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q
    Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced in vitro cellular uptake of P-gp substrate by poloxamer-modified liposomes (PMLs) in MDR cancer cells.
    Song CK; Balakrishnan P; Shim CK; Chung SJ; Kim DD
    J Microencapsul; 2011; 28(6):575-81. PubMed ID: 21770706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting.
    Ye P; Zhang W; Yang T; Lu Y; Lu M; Gai Y; Ma X; Xiang G
    Int J Nanomedicine; 2014; 9():2167-78. PubMed ID: 24855354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release.
    Nguyen VD; Zheng S; Han J; Le VH; Park JO; Park S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():104-114. PubMed ID: 28329728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation.
    Negi LM; Talegaonkar S; Jaggi M; Verma AK; Verma R; Dobhal S; Kumar V
    Colloids Surf B Biointerfaces; 2014 Nov; 123():600-9. PubMed ID: 25454761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of curcumin silica nanoparticle complexes conjugated with hyaluronic acid on colon cancer cells.
    Singh SP; Sharma M; Gupta PK
    Int J Biol Macromol; 2015 Mar; 74():162-70. PubMed ID: 25511568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma.
    Negi LM; Jaggi M; Joshi V; Ronodip K; Talegaonkar S
    Int J Biol Macromol; 2015 Jan; 72():569-74. PubMed ID: 25220787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
    Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
    Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamic evaluation of hyaluronic acid-modified imatinib-loaded PEGylated liposomes in CD44-positive Gist882 tumor-bearing mice.
    Huang J; Chen J
    J Liposome Res; 2024 Mar; 34(1):97-112. PubMed ID: 37401372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
    Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
    Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
    PalamĂ  IE; Coluccia AM; Gigli G
    Nanomedicine (Lond); 2014 Jul; 9(14):2087-98. PubMed ID: 24364873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronic acid-coated liposomes for active targeting of gemcitabine.
    Arpicco S; Lerda C; Dalla Pozza E; Costanzo C; Tsapis N; Stella B; Donadelli M; Dando I; Fattal E; Cattel L; Palmieri M
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):373-80. PubMed ID: 23791684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-Responsive hyaluronated liposomes for docetaxel delivery.
    Lee JM; Park H; Oh KT; Lee ES
    Int J Pharm; 2018 Aug; 547(1-2):377-384. PubMed ID: 29902507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic Acid-Based pH-Sensitive Polymer-Modified Liposomes for Cell-Specific Intracellular Drug Delivery Systems.
    Miyazaki M; Yuba E; Hayashi H; Harada A; Kono K
    Bioconjug Chem; 2018 Jan; 29(1):44-55. PubMed ID: 29183110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.